| Singh, Dave |
TRECOS, NCT06264674: Comparison Between CHF5993 pMDI 200/6/12.5 µg HFA-152a VS CHF5993 pMDI 200/6/12.5 µg HFA-134a in Subjects With Asthma (). |
|
|
| Active, not recruiting | 3 | 837 | Europe, RoW | CHF5993 200/6/12.5 μg pMDI HFA-152a, HFA-152a propellant, Inhaler CHF5993 200/6/12.5 μg pMDI HFA-134a, HFA-134a propellant | Chiesi Farmaceutici S.p.A. | Asthma | 07/25 | 09/25 | | |
| Completed | 2 | 337 | Europe, Canada, US, RoW | Tezepelumab, Placebo | AstraZeneca, Amgen | Chronic Obstructive Pulmonary Disease (COPD) | 11/23 | 01/24 | | |
|
NCT06166056: A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled CHF6333 After Single Doses in Healthy Volunteers and After Single and Repeated Doses in Subjects With Bronchiectasis |
|
|
| Recruiting | 1/2 | 45 | Europe | CHF6333, CHF6333 Placebo | Chiesi Farmaceutici S.p.A. | Bronchiectasis | 06/25 | 06/25 | | |
NCT04769869: A Clinical Trial in Healthy Volunteers and Patients With Mild Asthma to Investigate a New Medicine (AZD4604) for the Treatment of Asthma |
|
|
| Completed | 1 | 110 | Europe | AZD4604 for inhalation via DPI, Placebo for AZD4604 for inhalation via DPI, AZD4604 for IV administration, AZD4604 for oral administration | AstraZeneca | Asthma | 01/23 | 01/23 | | |
| Completed | 1 | 117 | Europe | KN-002 | Kinaset Therapeutics Inc | Asthma COPD | 12/23 | 07/24 | | |
NCT05195008: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics, With Target Occupancy Study of BIIB113 in Healthy Participants |
|
|
| Completed | 1 | 72 | Europe | BIIB113, BIIB113-Matching Placebo, 11^C]BIO-1819578 | Biogen | Healthy Volunteer | 07/23 | 07/23 | | |
| Recruiting | 1 | 120 | Europe | SPYVAC01 | SpyBiotech Limited | Cytomegalovirus Infections | 04/25 | 04/25 | | |
NCT06154837: A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease |
|
|
| Recruiting | 1 | 130 | Europe | GSK3862995B, Placebo | GlaxoSmithKline | Pulmonary Disease, Chronic Obstructive | 04/26 | 04/26 | | |
| Terminated | 1 | 78 | Europe, RoW | ARO-MUC5AC, Placebo | Arrowhead Pharmaceuticals, Arrowhead Pharmaceuticals, Inc. | Asthma, Chronic Obstructive Pulmonary Disease | 11/24 | 11/24 | | |
NCT05965089: A First in Human Study of AX-202 in Healthy Subjects and Patients With Psoriasis. |
|
|
| Completed | 1 | 58 | Europe | Placebo, AX-202 | Arxx Therapeutics | Healthy Volunteers, Mild to Moderate Psoriasis | 07/24 | 07/24 | | |
NCT06433921: A Study to Compare the Relative Potency of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152a to HFA-134a in Mild Asthmatics Aged 18 to 65 Inclusive |
|
|
| Recruiting | 1 | 91 | Europe | Salbutamol HFA-152a, Salbutamol HFA-134a, Placebo | GlaxoSmithKline | Asthma, Mild Asthma | 03/25 | 03/25 | | |
| Chaudhuri, Nazia |
| Terminated | 3 | 372 | Europe, US, RoW | Pamrevlumab, FG-3019, Placebo | FibroGen | Idiopathic Pulmonary Fibrosis | 09/23 | 09/23 | | |
|
| Completed | 2 | 80 | Europe, US | Orvepitant Maleate, Placebo | Nerre Therapeutics Ltd., Pharm-Olam International | Cough, Idiopathic Pulmonary Fibrosis | 06/24 | 06/24 | | |
